Australia: A highly attractive environment for drug development
Australia offers a highly favorable environment for drug research and development, with a mature infrastructure and experienced, capable local resources and expertise. Considering global geopolitical uncertainties, Australia presents a compelling option for sponsors to consider. This first article in a three-part series illustrates the Australian economy, demographics, healthcare investments and expenditures, and the growth of the pharmaceutical market and clinical trials. Ensuing articles will explore the landscape for clinical trials, including the therapeutic areas, the strength of patient centricity and innovation adoption, and the regulatory and reimbursement environment.
Interested in more? Check out part 2 and part 3.
Related Insights
Blog
A hybrid model supports globally diverse site participation for a retrospective cancer study
Jul 24, 2023
Article
Can Chinese Phase I data from the West accelerate China drug development?
Mar 17, 2021
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Video
Insights with Goldman Sachs Part 1: Future predictions
Jan 26, 2024
Blog
Adoption of the ICH Q12 guideline: New Horizons for Efficient Product Supply Chain Management for a Key Global Market
Nov 13, 2023
Blog
Removing barriers through pragmatic clinical trials
Oct 12, 2023
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Article
Australia: Infrastructure and Innovations for Clinical Trials
Aug 28, 2023
Blog
Ensuring future success in a new market by delivering a robust safety database solution
Aug 4, 2023
Video
The science and practice of ethnobridging
May 17, 2023
Blog
Toward more inclusive studies: Reaching and retaining patients from underrepresented communities
Apr 25, 2022
Article
How emerging biotechs can enter the Chinese market and prosper
Jan 18, 2022
Related Insights
Blog
A hybrid model supports globally diverse site participation for a retrospective cancer study
Jul 24, 2023
Article
Can Chinese Phase I data from the West accelerate China drug development?
Mar 17, 2021
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Video
Insights with Goldman Sachs Part 1: Future predictions
Jan 26, 2024
Blog
Adoption of the ICH Q12 guideline: New Horizons for Efficient Product Supply Chain Management for a Key Global Market
Nov 13, 2023
Blog
Removing barriers through pragmatic clinical trials
Oct 12, 2023
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Article
Australia: Infrastructure and Innovations for Clinical Trials
Aug 28, 2023
Blog
Ensuring future success in a new market by delivering a robust safety database solution
Aug 4, 2023
Video
The science and practice of ethnobridging
May 17, 2023
Blog
Toward more inclusive studies: Reaching and retaining patients from underrepresented communities
Apr 25, 2022
Article
How emerging biotechs can enter the Chinese market and prosper
Jan 18, 2022